The right diagnostic work-up: investigating renal and renovascular disorders

Renovascular disease is present in about 10-40% of patients with end-stage renal disease, and constitutes the fastest-growing group of end-stage renal disease patients. The unselective correction of renal artery stenosis has led to disappointing results. Most studies that have compared conservative...

Full description

Saved in:
Bibliographic Details
Published inJournal of hypertension. Supplement Vol. 21; no. 2; p. S19
Main Authors Radermacher, Jörg, Haller, Hermann
Format Journal Article
LanguageEnglish
Published England 01.05.2003
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:Renovascular disease is present in about 10-40% of patients with end-stage renal disease, and constitutes the fastest-growing group of end-stage renal disease patients. The unselective correction of renal artery stenosis has led to disappointing results. Most studies that have compared conservative treatment with angioplasty have found only modest or no beneficial effects of angioplasty on renal function and blood pressure. It is therefore mandatory to evaluate the functional significance of a stenosis before intervention. Patients most likely to respond favourably to revascularization should be identified. Factors that affect outcome include the severity of renal artery stenosis, type of treatment of renal artery stenosis and, most importantly, underlying renal disease, which prevents a favourable response even after successful correction of renal artery stenosis. Doppler ultrasonography to evaluate the renal resistance index [1 - (end diastolic velocity/maximum systolic velocity) x 100] or captopril scintigraphy are the best methods by which to classify patients as responders or non-responders to intervention. In patients with a renal resistance index > or = 80%, improvement of renal function or blood pressure is highly unlikely, despite successful correction of renal artery stenosis. The value of the renal resistance index can also be extended to patients with non-stenotic renal diseases. Identifying patients at risk for irreversible loss of renal function and who may benefit from intervention is a high research priority.
ISSN:0952-1178
DOI:10.1097/00004872-200305002-00004